SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2000 / Cilt: 48 - Sayı: 2

The effects of pnemuococcal polysaccharide vaccine to IgG and IgG2 responses in chronic obstructive pulmonary disease (Copd) and asthma

Kronik obstrüktif akciğer hastalığı (KOAH) ve astmada polisakkarid pnömokok aşısının IgG ve IgG2 düzeylerine etkisi

Fahriye KESKİN
Erdener BALIKÇI
İbrahim KATIRCIOĞLU
Recep BİNGÖL
Hüseyin ÇEBİ
İlknur EGECE
Oktay ÖZKARAKAŞ
Füsun YILDIZ
Pages
136–139
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We have concluded that clinic use of pneumococcal vaccines provide protection for patients in risk groups such as COPD and asthma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:"Streptococcus pneumoniae" is a very potent agent for human beings and is responsible for 50% of community acquired pneumoniaes.
📊
Key Findings & Data:This ratio increases in certain risk groups which include Chronic Obstructive Pulmonary Disease (COPD) and bronchial asthma.
💡
Conclusion & Impact:We have concluded that clinic use of pneumococcal vaccines provide protection for patients in risk groups such as COPD and asthma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

"Streptococcus pneumoniae" is a very potent agent for human beings and is responsible for 50% of community acquired pneumoniaes. This ratio increases in certain risk groups which include Chronic Obstructive Pulmonary Disease (COPD) and bronchial asthma. Thus, 46 patients were vaccinated by Pneumo 23 (Pasteur Merieux Connaught). Antibody levels: IgG and IgG2 were measured by ELISA method. Results were compared with 42 normal sera. Low titres of protective IgG levels were found in 28/46 (60.9%) patients before vaccination. After vaccination high titres of protective IgG levels were measured in 44/46 (95.7%) patients. The percentage of patients who had protective levels IgG2 before and after vaccination were found as 10/46 (21.7%) and 34/46 (73.9%) respecively. When we compared IgG and IgG2 levels before and after vaccination, both levels were found to be significantly increased (p< 0.05). We have concluded that clinic use of pneumococcal vaccines provide protection for patients in risk groups such as COPD and asthma.

Özet

"Streptococcus pneumoniae" insanlar için oldukça potent bir ajandır ve toplumsal kökenli pnomonilerin %50'sinden sorumludur. Bu oran KOAH ve astım gibi hastalıkları da içeren bazı belirli risk gruplarında daha da artar. Bu yüzden 46 hastayı Pneumo 23 (Pasteur Merieux Connaught) aşısı ile aşılayarak oluşan IgG ve IgG2 antikor seviyelerini ELISA yöntemi ile saptadık ve sonuçları 42 sağlıklı bireyin serumu ile karşılaştırdık. 28/46 (%60.9) hastada aşılama öncesi düşük titrelerde IgG ölçümlendi. Aşılama sonrası ise 44/46 (%95.7) hastada yüksek titrelerde koruyucu IgG saptandı. Aşılama öncesi ve sonrası koruyucu IgG2 seviyeleri sırasıyla 10/46 (%21.7) ve 34/46 (%73.9) olarak bulundu. Aşılama öncesi ve sonrası IgG ve IgG2 seviyeleri karşılaştırıldığında her ikisinde de istatistiksel olarak anlamlı artış saptandı (p< 0.05). Bu bulgular bize KOAH ve astım gibi risk grubu hastalarda pnömokok aşısının klinik kullanımının koruyucu özelliği olduğunu gösterdi.

🔖

Cite This Article

KESKİN, F., BALIKÇI, E., KATIRCIOĞLU, İ., BİNGÖL, R., ÇEBİ, H., EGECE, İ., ÖZKARAKAŞ, O., YILDIZ, F. (2022). The effects of pnemuococcal polysaccharide vaccine to IgG and IgG2 responses in chronic obstructive pulmonary disease (Copd) and asthma. Tüberküloz ve Toraks, Cilt: 48 - Sayı: 2, 136–139. https://ajindex.com/articles/619461

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Headlund JU, Kalin ME, Örtqvist AB, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly Patients Recently Treated for Pneumonia. Arch intern Med 1994; 154: 1961-5
  2. Morbidity and Mortality Weekly Report (MMWR). Prevention of pneumococcal disease. 1997; 46; 2
  3. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. JAMA 1993; 270: 1826-31
  4. American Thoracic Society. Definitions,epidemiology, pathophysiology, diagnosis and staging. Am J Respir Crit Care Med 1995; 152: 78
  5. Bolan G, Broome CV, Facklam RF, et al. Pneumococcal Vaccine Efficacy in selected populations in the United States. Annals of Internal Medicine 1986; 104(1): 1-6
  6. Loeliger AE, Kijgers Gl, Aerts P, et al. Deficient Antipne-umococcal Polysaccharide responses in HIV seropositive patients. Immunol Med Microbiol 1995; 12(1): 33-41
  7. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148; 1136-59
  8. Sims RV, Steinmann Wc, WcConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-7
  9. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine N Eng J Med 1991; 325: 1453-60
  10. Sorensen UBS, Henrichsen J. Cross-reactions between pnomococci and other streptococci due to C-polysaccharide and F antigen. J Clin Microbiol 1987; 25: 1854-9
  11. Musher DM, Luchi MJ, Watson DA, et al. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: Determination of IgG responses by Elisa and the effect of adsorption of serum with non type specifîc cell wall polysaccharide. The Journal of Infectious Diseases 1990; 161:553-6
  12. Fletcher TS, Tunnicliffe WS, Hammond K, et al. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory failure. BMJ 1997; 314: 1663-5
  13. Yüce A, Uçan ES, Sayan M, et al. Astım ue KOAH'lı hastalarda pnömokok polisakkarit aşısının koruyuculuğu.8. Türk Mikrobiyoloji ve Enfeksiyon Hastalıkları Kongresi,6-10 Ekim 1997, Dedeman Oteli,Antalya. 14.Musher DM.Infections caused by Steptococcus pneumoniae;clinical spectrum,pathogenesis,immunity and treatment,Clin Infest Dis 1992;14:801-9.